Mari Nygård

Mari Nygård started at the Cancer Registry in 2001, first as a researcher and later as head of the Department of Research. Mari is a medical doctor from the University of Tartu, Estonia and obtained her doctorate in epidemiology in 2001 from the University of Tampere, Finland. Her research mainly focuses on HPV-related cancers, including cervical cancer and cervical cancer prevention. She actively contributes to the design of the national cervical cancer prevention plan and acts as an adviser to the World Health Organization in the work to eliminate cervical cancer globally.


Nygård received her MD from the University of Tartu, Estonia, in 1994, and her PhD in Epidemiology from the University of Tampere, Finland, in 2001.

Her previous work experience includes researcher at the National Public Health Institute in Finland, visiting scientist at Lawrence Livermore National Security, USA, and Visiting Professor at the University of Tartu, Estonia.

Nygård has been affiliated with the Cancer Registry of Norway since 2001.

Mari Nygård is the head of the Department of research.

Her research focuses mainly on HPV infection and related cancers, including cervical cancer, and cervical cancer prevention.

Nygård has also focused on the development of personalized cancer prevention and the use of risk- stratified algorithms.

Nygård actively contributes to shape cervical cancer prevention policy. Her efforts in the National expert groups for implementing HPV-based screening in Norway, resulted in policy changes in 2015, when HPV-test started to replace cytology as a primary screening test in Norway.

Nygård is acting as an advisor to the World Health Organization to accelerate Cervical Cancer Elimination activities.

She has also has been consulting with public health policy makers for cervical cancer prevention-related issues in Estonia, Romania, and Ganzu, China. Among the international projects Nygård participates in is a collaboration with the pharmaceutical company MSD where health register data is used to analyze the long-term effect of HPV vaccines.

Finally, Nygård is concerned with utilizing the research opportunities the Norwegian Health infrastructure and registries provide, and is a keen advocate for increased access to biobanks and health registries.

A list of all publications can be found in the ORCID link in the side pane on this site 

Kjaer SK, Nygård M, Sundström K, Munk C, Berger S, Dzabic M, Fridrich KE, Waldstrøm M, Sørbye SW, Bautista O, Group T, Luxembourg A (2021)
Long-term effectiveness of the nine-valent human papillomavirus vaccine in Scandinavian women: interim analysis after 8 years of follow-up
Hum Vaccin Immunother, 1-7
DOI 10.1080/21645515.2020.1839292, PubMed 33326342

Goncalves A, Soper B, Nygård M, Nygård JF, Ray P, Widemann D, Sales AP (2020)
Improving five-year survival prediction via multitask learning across HPV-related cancers
PLoS One, 15 (11), e0241225
DOI 10.1371/journal.pone.0241225, PubMed 33196642

Nygård M, Hansen BT, Kjaer SK, Hortlund M, Tryggvadóttir L, Munk C, Lagheden C, Sigurdardottir LG, Campbell S, Liaw KL, Dillner J (2020)
Human papillomavirus genotype-specific risks for cervical intraepithelial lesions
Hum Vaccin Immunother
DOI 10.1080/21645515.2020.1814097, PubMed 32990181

Soper BC, Nygård M, Abdulla G, Meng R, Nygård JF (2020)
A hidden Markov model for population-level cervical cancer screening data
Stat Med, 39 (25), 3569-3590
DOI 10.1002/sim.8681, PubMed 32854166

Kjaer SK, Nygård M, Sundström K, Dillner J, Tryggvadottir L, Munk C, Berger S, Enerly E, Hortlund M, Ágústsson ÁI, Bjelkenkrantz K, Fridrich K, Guðmundsdóttir I, Sørbye SW, Bautista O, Group T, Luxembourg A, Marshall JB, Radley D, Yang YS, Badshah C, Saah A (2020)
Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countries
EClinicalMedicine, 23, 100401
DOI 10.1016/j.eclinm.2020.100401, PubMed 32637895

Orumaa M, Kjaer SK, Dehlendorff C, Munk C, Olsen AO, Hansen BT, Campbell S, Nygård M (2020)
The impact of HPV multi-cohort vaccination: Real-world evidence of faster control of HPV-related morbidity
Vaccine, 38 (6), 1345-1351
DOI 10.1016/j.vaccine.2019.12.016, PubMed 31917039

Hansen BTKjaer SKArnheim-Dahlström LLiaw KLJuul KEThomsen LTFrederiksen KElfström KMMunk CNygård M (2019)
Age at first intercourse, number of partners and sexually transmitted infection prevalence among Danish, Norwegian and Swedish women: estimates and trends from nationally representative cross-sectional surveys of more than 100 000 women
Acta Obstet Gynecol Scand
DOI 10.1111/aogs.13732, PubMed 31529491

Drolet, M., Benard, E., Perez, N., Brisson, M., & Group, Boily MC, Ali H, Baldo V, Brassard P, Brotherton JML, Callander D, Checchi M, Chow EP, Cocchio S, Dalianis T, Deeks SL, Dehlendorff C, Donovan B, Fairley CK, Flagg EW, Gargano JW, Garland SM, Grün N, Hansen BT, Harrison C, Herweijer E, Imburgia TM, Johnson AM, Kahn JA, Kavanagh K, Kjaer SK, Kliewer EW, Liu B, Machalek DA, Markowitz L, Mesher D, Munk C, Niccolai L, Nygård M, Ogilvie G, Oliphant G, Pollock KG, Jesús M, Smith MA, Steben M, Söderlund-Strand A, Sonnenberg P, Sparen P, Tanton C, Wheeler CM, Woestenberg PJ, Yu BN. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis
Lancet 2019;394(10197):497-509
DOI: 10.1016/S0140-6736(19)30298-3

Kreimer ARFerreiro-Iglesias ANygard MBender NSchroeder LHildesheim ARobbins HAPawlita MLangseth HSchlecht NFTinker LFAgalliu ISmoller SWNess-Jensen EHveem KD'Souza GVisvanathan KMay BUrsin GWeiderpass EGiles GGMilne RLCai QBlot WJZheng W et al. (2019)
Timing of HPV16-E6 antibody seroconversion before OPSCC: findings from the HPVC3 consortium
Ann Oncol30 (8)1335-1343
DOI 10.1093/annonc/mdz138, PubMed 31185496

See all publications in PubMed